{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:15:32Z","timestamp":1781795732703,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.cllc.2018.06.001","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T21:05:06Z","timestamp":1529355906000},"page":"e803-e810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience"],"prefix":"10.1016","volume":"19","author":[{"given":"Srinivas","family":"Raman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa W.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthea","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bezjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C. John","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2018.06.001_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cllc.2016.10.008","article-title":"Radiotherapy with curative intent in patients with early-stage, medically inoperable, non\u2013small-cell lung cancer: a systematic review","volume":"18","author":"Falkson","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2018.06.001_bib2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.semradonc.2017.03.001","article-title":"Stereotactic ablative radiotherapy for early-stage lung cancer","volume":"27","author":"Shah","year":"2017","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib3","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijrobp.2015.10.040","article-title":"Primary study endpoint analysis for NRG Oncology\/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non\u2013small cell lung cancer (NSCLC)","volume":"94","author":"Bezjak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2018.06.001_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non\u2013small-cell lung cancer: what we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2018.06.001_bib7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non\u2013small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib8","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2016.11.1491","article-title":"Safety of stereotactic body radiotherapy for central, ultracentral, and paramediastinal lung tumors","volume":"12","author":"Daly","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13014-016-0732-5","article-title":"SBRT for centrally localized NSCLC\u2014what is too central?","volume":"11","author":"Roesch","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib11","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.ijrobp.2016.03.024","article-title":"Simple factors associated with radiation-induced lung toxicity after stereotactic body radiation therapy of the thorax: a pooled analysis of 88 studies","volume":"95","author":"Zhao","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2018.06.001_bib12","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ctrv.2016.10.002","article-title":"Stereotactic ablative radiotherapy for early stage non\u2013small cell lung cancer: a critical literature review of predictive factors of relapse","volume":"50","author":"Loganadane","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.cllc.2018.06.001_bib13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1470-2045(12)70242-5","article-title":"Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non\u2013small-cell lung cancer: a retrospective analysis","volume":"13","author":"Senthi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib14","doi-asserted-by":"crossref","first-page":"20160732","DOI":"10.1259\/bjr.20160732","article-title":"A\u00a0systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer","volume":"90","author":"Murray","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.cllc.2018.06.001_bib15","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non\u2013small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib16","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non\u2013small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.radonc.2011.12.018","article-title":"Radiographic changes after lung stereotactic ablative radiotherapy (SABR)\u2014can we distinguish recurrence from fibrosis? A systematic review of the literature","volume":"102","author":"Huang","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju164","article-title":"Phase II study of accelerated hypofractionated three-dimensional conformal radiotherapy for stage T1-3 N0 M0 non\u2013small cell lung cancer: NCIC CTG BR. 25","volume":"106","author":"Cheung","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2018.06.001_bib19","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/JTO.0000000000000260","article-title":"Toxicities of organs at risk in the mediastinal and hilar regions following stereotactic body radiotherapy for centrally located lung tumors","volume":"9","author":"Nishimura","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2014.02.011","article-title":"Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non\u2013small cell lung cancer","volume":"89","author":"Han","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2018.06.001_bib21","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2014.08.008","article-title":"Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy","volume":"90","author":"Modh","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2018.06.001_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2014.05.011","article-title":"Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity","volume":"90","author":"Stephans","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2018.06.001_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.radonc.2013.01.004","article-title":"Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review","volume":"106","author":"Senthi","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/JTO.0000000000000484","article-title":"Central versus peripheral tumor location: influence on survival, local control, and toxicity following stereotactic body radiotherapy for primary non\u2013small-cell lung cancer","volume":"10","author":"Park","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13014-018-1001-6","article-title":"Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?","volume":"13","author":"Murrell","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.cllc.2018.06.001_bib26","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for ultracentral non\u2013small-cell lung cancer\u2014a safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418301438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730418301438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:07:24Z","timestamp":1761505644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730418301438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1525730418301438"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2018.06.001","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2018.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}